GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (FRA:5FA) » Definitions » Cyclically Adjusted Revenue per Share

Nipro (FRA:5FA) Cyclically Adjusted Revenue per Share : €16.25 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nipro Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nipro's adjusted revenue per share for the three months ended in Dec. 2023 was €5.304. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €16.25 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Nipro's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nipro was 7.70% per year. The lowest was 5.50% per year. And the median was 6.40% per year.

As of today (2024-06-10), Nipro's current stock price is €7.15. Nipro's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €16.25. Nipro's Cyclically Adjusted PS Ratio of today is 0.44.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nipro was 0.99. The lowest was 0.41. And the median was 0.61.


Nipro Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Nipro's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro Cyclically Adjusted Revenue per Share Chart

Nipro Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 15.44 16.03 16.48 -

Nipro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.48 15.49 15.78 16.25 -

Competitive Comparison of Nipro's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Nipro's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nipro's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nipro's Cyclically Adjusted PS Ratio falls into.



Nipro Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nipro's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.304/106.8000*106.8000
=5.304

Current CPI (Dec. 2023) = 106.8000.

Nipro Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 3.264 95.700 3.643
201406 3.215 98.000 3.504
201409 3.378 98.500 3.663
201412 3.437 97.900 3.749
201503 3.847 97.900 4.197
201506 3.742 98.400 4.061
201509 3.997 98.500 4.334
201512 4.205 98.100 4.578
201603 4.336 97.900 4.730
201606 4.030 98.100 4.387
201609 4.163 98.000 4.537
201612 4.115 98.400 4.466
201703 4.045 98.100 4.404
201706 4.097 98.500 4.442
201709 3.897 98.800 4.213
201712 4.325 99.400 4.647
201803 4.231 99.200 4.555
201806 4.373 99.200 4.708
201809 4.398 99.900 4.702
201812 4.897 99.700 5.246
201903 4.643 99.700 4.974
201906 4.990 99.800 5.340
201909 5.290 100.100 5.644
201912 5.220 100.500 5.547
202003 5.452 100.300 5.805
202006 4.990 99.900 5.335
202009 5.059 99.900 5.408
202012 5.221 99.300 5.615
202103 5.424 99.900 5.799
202106 5.454 99.500 5.854
202109 5.872 100.100 6.265
202112 5.372 100.100 5.732
202203 5.223 101.100 5.517
202206 4.907 101.800 5.148
202209 5.073 103.100 5.255
202212 5.546 104.100 5.690
202303 5.275 104.400 5.396
202306 4.988 105.200 5.064
202309 5.001 106.200 5.029
202312 5.304 106.800 5.304

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Nipro  (FRA:5FA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nipro's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.15/16.25
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nipro was 0.99. The lowest was 0.41. And the median was 0.61.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nipro Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Nipro's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nipro (FRA:5FA) Business Description

Industry
Traded in Other Exchanges
Address
3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (FRA:5FA) Headlines

No Headlines